News

Article

AAO 2023: Norlase 4 years later

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Oliver Hvidt:

Hello, I'm Oliver Hvidt. I'm the CEO and co-founder of Norlase. We are really excited to be here at AAO 2023. Norlase's journey actually started right here in San Francisco at AAO 2019, where we launched our first laser photocoagulator, the LEAF. Since then, it's been an incredible journey for us. In just 4 short years we've gone on from 1 product to now 3 products in the market and to becoming one of the leading laser manufacturers in the industry. After launching LEAF in 2019, we came out with the LION, the world's first integrated indirect ophthalmoscope and laser in 2020. And last year, we were able to reveal the ECHO, the world's first truly portable and truly affordable pattern laser. We are now in more than 70 different markets worldwide. And we are approaching the delivery of our 700th laser system just 4 years into being on the market. So we really appreciate the reception of our products and our technology. What we strive towards is building lasers that are more user friendly, more compact, more affordable, and therefore allows ophthalmologists to operate more efficiently to the benefit of them and their patients. So we're really excited to be here and we look forward to seeing you at the show.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.